Liraglutide for patients with non-alcoholic steatohepatitis.
Inserm U1062, Inra U1260, Faculté de Médecine, Marseille, France; Aix Marseille Université, Marseille, France; Department of Endocrinology, Metabolic Diseases and Nutrition, Pole Endo, Marseille, France.
Bénédicte
B
Gaborit
Inserm U1062, Inra U1260, Faculté de Médecine, Marseille, France; Aix Marseille Université, Marseille, France; Department of Endocrinology, Metabolic Diseases and Nutrition, Pole Endo, Marseille, France.
Patrice
P
Darmon
Inserm U1062, Inra U1260, Faculté de Médecine, Marseille, France; Aix Marseille Université, Marseille, France.
Patricia
P
Ancel
Inserm U1062, Inra U1260, Faculté de Médecine, Marseille, France; Aix Marseille Université, Marseille, France; Department of Endocrinology, Metabolic Diseases and Nutrition, Pole Endo, Marseille, France. Electronic address: anne.dutour@ap-hm.fr.
Anne
A
Dutour
D005260:Female; D006801:Humans; D054795:Incretins / Q000008:administration & dosage*; D000069450:Liraglutide / Q000008:administration & dosage*; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*
D054795:Incretins; D000069450:Liraglutide